ArticleInternational journal of clinical and experimental pathology2010
p16INK4a expression in basal-like breast carcinoma.
Article in International journal of clinical and experimental pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- The paradox of senescent-marker positive cancer cells: challenges and opportunities.npj aging · 2024Review
- The Prognostic Significance of P16 Immunohistochemical Expression Pattern in Women with Invasive Ductal Breast Carcinoma.Reports of biochemistry & molecular biology · 2023Article
- Review
- Breast Cancer and p16: Role in Proliferation, Malignant Transformation and Progression.Healthcare (Basel, Switzerland) · 2021Article
- Differential and correlated expressions of p16/p21/p27/p38 in mammary gland tumors of aged dogs.Journal of veterinary science · 2017Article
- p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer.Oncotarget · 2016Article
- Article
- Estrogen receptor α-coupled Bmi1 regulation pathway in breast cancer and its clinical implications.BMC cancer · 2014Article
- The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer.Breast cancer research : BCR · 2013Article
- p16 expression correlates with basal-like triple-negative breast carcinoma.Ecancermedicalscience · 2013Article
- A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.Diagnostic pathology · 2012Article
- Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer.Journal of oncology · 2012Article
- Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Article
- Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets.Sarcoma · 2011Article
- Prognostic Significance of p16 Protein Expression in Breast Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BLBC represents a distinctive group of invasive breast carcinomas with specific genotype and immunoprofile. BLBC is usually defined by gene expression profiling and is currently associated with poor outcome. BLBCs are estrogen receptor (ER) negative, progesterone receptor (PgR) negative, HER2 negative, and usually show a variable expression of basal cytokeratins (CKs), EGFR and CD117. p16(INK4a) is a tumor suppressor protein, encoded by the CDKN2A gene, which regulates cell cycle. The reported association of abnormalities in the p16/Rb pathway with increased risk of malignancy prompted us to determine the expression of p16(INK4a) in a group of BLBC; the results were compared with a group of high-grade invasive carcinoma (HG-IC) of breast. Tissue microarrays (TMA) were constructed in triplicate including 18 BLBC and 18 HG-IC. All BLBC cases were ER-/PgR-/HER2-. Seventeen (94%) BLBC were CK 5/6+/CK 14+; 14 (78%) BLCB showed EGFR expression and 13 (72%) were CD117 positive. BLBCs showed a strong positive reaction with p16(INK4a) antibody in 16 of 18 (89%) cases. Although the significance of p16(INK4a) expression in breast cancer is not fully understood, we have shown that p16(INK4a) is strongly expressed in breast cancers with basal-like phenotype. Since it is known that p16(INK4a) is associated with aggressive behavior in human carcinomas, these data suggest that p16(INK4a) play a role in the poor prognosis of BLBC.
Indexed as
Identifiers
20661408PMC2907122W1550747689What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.